🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07183891
Recruiting Observational

Performance of Large Language Models for Structured Recognition and Refractive Prediction

NCT07183891 · tracked via the Priya Life Science China tracker
Sponsor
Jin Yang
Phase
Observational
Started
2025-08-01
Last updated
2025-09-19

Condition(s) studied

Cataract

Study summary

We conducted a single-center, retrospective observational study to evaluate large language models (ChatGPT 4o, GPT-5, DeepSeek) for automated interpretation of de-identified IOLMaster 700 reports provided as raster images. Models produced structured biometric extraction, toric IOL recommendation, and refractive predictions (sphere, cylinder, axis). Primary outcomes included parameter-level agreement and refractive error metrics; secondary outcomes included decision-support performance for toric IOL selection and agreement on ordered T-codes. No clinical intervention was performed.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: -postoperative corrected distance visual acuity (CDVA) of 0.10 logMAR or better -an absolute IOL rotational stability of less than 10∘ at the 1-month follow-up examination Exclusion Criteria: * incomplete biometric data on the examination report; * a history of previous ocular surgery or ocular trauma * the occurrence of intraoperative complications, such as an anterior capsular tear or posterior capsular rupture * the development of significant postoperative complications, including but not limited to severe intraocular infection or inadequate pupillary dilation.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Eye and ENT hospital of Fudan University Shanghai Shanghai Municipality Recruiting

More Jin Yang trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07183891 on ClinicalTrials.gov ↗ ← All trials in China